Cryptococcosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Cryptococcosis is an infection caused by Cryptococcus neoformans fungus. Symptoms include cough, fatigue, fever, headache, nausea, and skin rashes. Predisposing factors are most often seen in people with a weakened immune system, such as those with HIV infection, taking high doses of corticosteroid medications, cancer chemotherapy, or who have Hodgkin’s disease. Treatment includes anti-fungal drugs.

The Cryptococcosis drugs in development market research report provide comprehensive information on the therapeutics under development for Cryptococcosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cryptococcosis and features dormant and discontinued projects.

Key Targets in the Cryptococcosis Pipeline Products Market

The key targets in the Cryptococcosis pipeline products market are Lanosterol 14 Alpha Demethylase, Cell Membrane, Glucosylceramide, and GPI Anchored Wall Transfer Protein 1.

Cryptococcosis Pipeline Products Analysis Market by Targets

Cryptococcosis Pipeline Products Analysis Market by Targets

For more target insights, download a free report sample

Key Mechanisms of Action in the Cryptococcosis Pipeline Products Market

The key mechanisms of action in the Cryptococcosis pipeline products market are Lanosterol 14 Alpha Demethylase Inhibitor, Cell Membrane Disruptor, and GPI Anchored Wall Transfer Protein 1 Inhibitor.

Cryptococcosis Pipeline Products Market Analysis by Mechanism of Actions

Cryptococcosis Pipeline Products Market Analysis by Mechanism of Actions

For more mechanism of actions insights, download a free report sample

Key Routes of Administration in the Cryptococcosis Pipeline Products Market

The key routes of administration in the Cryptococcosis pipeline products market are intravenous, oral, and inhalational.

Cryptococcosis Pipeline Products Market Analysis by Routes of Administration

Cryptococcosis Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Cryptococcosis Pipeline Products Market

The key molecule types in the Cryptococcosis pipeline products market are small molecule, monoclonal antibody, synthetic peptide, and vaccine.

Cryptococcosis Pipeline Products Market Analysis by Molecule Type

Cryptococcosis Pipeline Products Market Analysis by Molecule Type

For more molecule type insights, download a free report sample

Major Companies in the Cryptococcosis Pipeline Products Market

The major companies in the Cryptococcosis pipeline products market are Amtixbio Co Ltd, Basilea Pharmaceutica Ltd, Collaborations Pharmaceuticals Inc, MicroRid Technologies Inc, Mycovia Pharmaceuticals Inc, Novabiotics Ltd, Pfizer Inc, Pulmocide Ltd, Pulmonomy Inc, REYON Pharmaceutical Co Ltd, and Visterra Inc.

Cryptococcosis Pipeline Products Market Analysis by Companies

Cryptococcosis Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

Market Report Overview

Key targets Lanosterol 14 Alpha Demethylase, Cell Membrane, Glucosylceramide, and GPI Anchored Wall Transfer Protein 1
Key mechanism of action Lanosterol 14 Alpha Demethylase Inhibitor, Cell Membrane Disruptor, and GPI Anchored Wall Transfer Protein 1 Inhibitor
Key routes of administration Intravenous, Oral, and Inhalational
Key molecule type Small Molecule, Monoclonal Antibody, Synthetic Peptide, and Vaccine
Major companies Amtixbio Co Ltd, Basilea Pharmaceutica Ltd, Collaborations Pharmaceuticals Inc, MicroRid Technologies Inc, Mycovia Pharmaceuticals Inc, Novabiotics Ltd, Pfizer Inc, Pulmocide Ltd, Pulmonomy Inc, REYON Pharmaceutical Co Ltd, and Visterra Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cryptococcosis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Cryptococcosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cryptococcosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cryptococcosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Cryptococcosis (Infectious Disease)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cryptococcosis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cryptococcosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Amtixbio Co Ltd
Basilea Pharmaceutica Ltd
Collaborations Pharmaceuticals Inc
MicroRid Technologies Inc
Mycovia Pharmaceuticals Inc
Novabiotics Ltd
Pfizer Inc
Pulmocide Ltd
Pulmonomy Inc
REYON Pharmaceutical Co Ltd
Visterra Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cryptococcosis – Overview

Cryptococcosis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cryptococcosis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cryptococcosis – Companies Involved in Therapeutics Development

Amtixbio Co Ltd

Basilea Pharmaceutica Ltd

Collaborations Pharmaceuticals Inc

MicroRid Technologies Inc

Mycovia Pharmaceuticals Inc

Novabiotics Ltd

Pfizer Inc

Pulmocide Ltd

Pulmonomy Inc

REYON Pharmaceutical Co Ltd

Visterra Inc

Cryptococcosis – Drug Profiles

Drugs for Cryptococcosis – Drug Profile

Product Description

Mechanism Of Action

fosmanogepix – Drug Profile

Product Description

Mechanism Of Action

History of Events

isavuconazonium sulfate – Drug Profile

Product Description

Mechanism Of Action

History of Events

NP-339 – Drug Profile

Product Description

Mechanism Of Action

PC-1244 – Drug Profile

Product Description

Mechanism Of Action

RY-108 – Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Cryptococcosis – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules for Fungal Infections – Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Fungal Infections – Drug Profile

Product Description

Mechanism Of Action

TCPMY-123 – Drug Profile

Product Description

Mechanism Of Action

Vaccine to Target Glucosylceramide for Fungal Infections – Drug Profile

Product Description

Mechanism Of Action

VIS-FNG – Drug Profile

Product Description

Mechanism Of Action

History of Events

VT-1598 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Cryptococcosis – Dormant Projects

Cryptococcosis – Discontinued Products

Cryptococcosis – Product Development Milestones

Featured News & Press Releases

Sep 30, 2021: Basilea’s partner Asahi Kasei Pharma filed New Drug Application for the marketing authorization of isavuconazole in Japan

Jul 26, 2021: Basilea’s partner Asahi Kasei Pharma prepares NDA filing for the marketing authorization of isavuconazole in Japan based on positive phase 3 study results

Sep 09, 2019: FDA grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for seven different indications

Feb 11, 2019: FDA grants orphan drug designation to Amplyx Pharmaceuticals for APX001 for treatment of cryptococcosis

Apr 18, 2018: Basilea reports start of clinical phase 3 study in Japan by Asahi Kasei Pharma with antifungal isavuconazole

Mar 12, 2018: Amplyx Pharmaceuticals Receives Fourth Qualified Infectious Disease Product Designation from the FDA for APX001

Jun 27, 2016: New Promise Against Deadly Global Fungal Infections

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Cryptococcosis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Cryptococcosis – Pipeline by Amtixbio Co Ltd, 2022

Cryptococcosis – Pipeline by Basilea Pharmaceutica Ltd, 2022

Cryptococcosis – Pipeline by Collaborations Pharmaceuticals Inc, 2022

Cryptococcosis – Pipeline by MicroRid Technologies Inc, 2022

Cryptococcosis – Pipeline by Mycovia Pharmaceuticals Inc, 2022

Cryptococcosis – Pipeline by Novabiotics Ltd, 2022

Cryptococcosis – Pipeline by Pfizer Inc, 2022

Cryptococcosis – Pipeline by Pulmocide Ltd, 2022

Cryptococcosis – Pipeline by Pulmonomy Inc, 2022

Cryptococcosis – Pipeline by REYON Pharmaceutical Co Ltd, 2022

Cryptococcosis – Pipeline by Visterra Inc, 2022

Cryptococcosis – Dormant Projects, 2022

Cryptococcosis – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Cryptococcosis, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Cryptococcosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Cryptococcosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Cryptococcosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.